A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

Trial Profile

A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs ABY 035 (Primary)
  • Indications Psoriasis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms AFFIRM-35
  • Sponsors Affibody
  • Most Recent Events

    • 18 Jul 2018 Planned End Date changed from 7 Sep 2019 to 31 Jul 2019.
    • 21 Mar 2018 According to a Affibody media release, the first patient has been dosed in this study.
    • 17 Nov 2017 According to a Affibody Medical AB media release, the German regulatory agency BfArM approved the clinical trial application (CTA) for the Phase II study with ABY-035 in Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top